Changing trends in end-stage renal disease due to diabetes in the United Kingdom

Journal of Renal Care

Volumn 38, Issue SUPPL. 1, 2012, Pages 12-22

  Hill, C J ^a   Fogarty, D G ^a,b,c  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UK RENAL REGISTRY   (United Kingdom)

Author keywords

Diabetic nephropathy; Dialysis; Incidence; Late presentation; Renal replacement therapy

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; HUMAN; INCIDENCE; MORTALITY; SURVIVAL; UNITED KINGDOM;

DIABETIC NEPHROPATHIES; GREAT BRITAIN; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; SURVIVAL ANALYSIS;

EID: 84856909934     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2012.00273.x     Document Type: Article

References (36)

1. Ansell D. & Tomson C.R.V. (2009). UK Renal Registry Annual Report (December 2008): Chapter 15. The UK Renal Registry, UKRR database, validation and methodology. Nephron Clinical Practice 111(Suppl 1), 277-285.
2. Cameron J.S. (2002). A History of the Treatment of Renal Failure by Dialysis. Oxford : Oxford University Press.
3. Campbell S.M., Reeves D., Kontopantelis E. et al (2009). Effects of pay for performance on the quality of primary care in England. New England Journal of Medicine 361, 368-378.
4. Castledine C., Steenkamp R., Feest T. et al (2011). Survival and causes of death of UK adult patients on renal replacement therapy in 2009: national and centre-specific analyses. Nephron Clinical Practice 119(Suppl 2), 119-134.
5. De Boer I.H., Rue T.C., Hall Y.N. et al (2011). Temporal trends in the prevalence of diabetic kidney disease in the United States. Journal of the American Medical Association 305, 2532-2539.
6. Douzdjian V., Rice J.C., Gugliuzza K.K. et al (1996). Renal allograft and patient outcome after transplantation: pancreas-kidney versus kidney-alone transplants in type 1 diabetic patients versus kidney-alone transplants in non-diabetic patients. American Journal of Kidney Diseases 27, 106-116.
7. Feest T.G., Mistry C.D., Grimes D.S. et al (1990). Incidence of advanced chronic renal failure and the need for end-stage renal replacement treatment. British Medical Journal 301, 897-900.
8. Gaede P., Vedel P., Larsen N. et al (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 348, 383-393.
9. Ghouddosi K., Ramezani M.K., Assari S. et al (2007). Primary kidney disease and post-renal transplantation hospitalization costs. Transplant Proceedings 39, 962-965.
10. Gilg J., Castledine C., Fogarty D. et al (2011). UK RRT incidence in 2009: national and centre-specific analysis. Nephron Clinical Practice 119(Suppl 2), 1-25.
11. Haller H., Ito S., Izzo J.L., Jr., et al (2011). Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New England Journal of Medicine 364, 907-917.
12. Hallan S.I., Ritz E., Lydersen S. et al (2009). Combining GFR and albu-minuria to classify CKD improves prediction of ESRD. Journal of American Society of Nephrology 20(5), 1069-1077.
13. Jerums G., Allen T.J., Campbell D.J. et al (2001). Long term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. American Journal of Kidney Diseases 37, 890-899.
14. Jones C.A., Krolewski A.S., Rogus J. et al (2005). Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney International 67, 1-8.
15. Levey A.S., Atkins R., Coresh J. et al (2007). Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney International 72, 247-259.
16. Lewis E.J., Hunsicker L.G., Clarke W.R. et al (2001). Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345, 851-860.
17. MacIsaac R.J. & Jerums G. (2011). Diabetic kidney disease with and without albuminuria. Current Opinion in Nephrology and Hypertension 20, 246-257.
18. Magee G.M., Hunter S.J., Cardwell C.R. et al (2010). Identifying additional patients with diabetic nephropathy using the UK primary care initiative. Diabetic Medicine 27(12), 1372-1378.
19. Mogensen C.E. (1976). Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scandinavian Journal of Clinical and Laboratory Investigation 36, 383-388.
20. National Diabetes Audit. (2010). Available from: diabetesaudits (accessed June 2011).
21. Parving H.H., Andersen A.R., Smidt U.M. et al (1983). Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1, 1175-1179.
22. Perkins B.A., Ficociello L.H., Silva F.H. et al (2003). Regression of microalbuminuria in type 1 diabetes mellitus. New England Journal of Medicine 348, 2285-2293.
23. Ravanan R., Udayaraj U., Ansell D. et al (2010). Variation between centres in access to renal transplantation in UK: longitudinal cohort study. British Medical Journal 341, c3451, doi:
24. Sampaio M.S., Kuo H.T. & Bunnapradist S. (2011). Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. Clinical Journal of the American Society of Nephrology 6, 1198-1206.
25. Sarafidis P.A., Stafylas P.C., Kanaki A.I. et al (2008). Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. American Journal of Hypertension 21(8), 922-929.
26. Steenkamp R., Castledine C., Feest T. et al (2011). UK RRT prevalence in 2009: national and centre specific analyses. Nephron Clinical Practice 119(Suppl 2), 27-52.
27. Stel V.S., van de Luijtgaarden M.W.M., Wanner C. et al (2011). The 2008 ERA-EDTA Registry Annual Report-a précis. Nephrology Dialysis Transplantation 4, 1-13.
28. The Diabetes Control and Complications Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329, 977-986.
29. UK Renal Registry (UKRR). (1998). Patients starting renal replacement therapy in 1996 and 1997. In The First Annual Report of the UK Renal Registry. Bristol : UK Renal Registry.
30. UK Renal Registry (UKRR). (2005). New adult patients starting renal replacement therapy in the UK in 2004. In The Eighth Annual Report of the UK Renal Registry. Bristol : UK Renal Registry.
31. UK Renal Registry (UKRR). (2009). Appendix D: Methodology used for analyses of PCT/local authority incidence and prevalence rates and of standardised ratios. Nephron Clinical Practice 111 (S1), 302-304.
32. UK Renal Registry (UKRR). (2011). The Thirteenth Annual Report of the Renal Association. Nepron Clinical Practice 119 (S2).
33. United Kingdom Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853.
34. United States Renal Data System (USRDS). (2010). Excerpts from the USRDS 2009 annual data report: atlas of end-stage renal disease in the United States. American Journal of Kidney Diseases 55 (Suppl 1), 231-240.
35. Wolfe R.A., Ashby V.B., Milford E.L. et al (1999). Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. New England Journal of Medicine 341, 1725-1730.
36. World Health Organisation (WHO) Data and Statistics. (2011). Available from: (accessed June 2011).